Epizyme, Inc.
EZH2 inhibitors for treating cancer

Last updated:

Abstract:

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Status:
Grant
Type:

Utility

Filling date:

16 Jun 2017

Issue date:

19 Oct 2021